What is Corporate Leadership? While operating responsibly should always take priority, Corporate Leadership requires us to focus on the very nature of our activities, going even deeper than our actions around Corporate Social Responsibility. This aspect of leadership defines the character of an entity, the impressions often left in its wake, and holds the tone across the organization and all its choices.

In the Life Sciences industry, corporations have unique advantages that smaller research and academic institutions often struggle with: resources and velocity. Private Equity and income generation provide more attainable financial support, and dedicated teams with cyclical workstreams allow for expediency when reaching for outcomes. The effective application of these resources to timely and impactful initiatives related to human health, environmental science, and the convergence of biology and technology is crucial for corporations looking to lead our society towards a better world.

Corporate leadership also paves the path forward to enable those who will hold the torch of leadership. This includes whose and what programs are supported and uplifted to succeed and allocating resources to focus on important efforts that help make what may have been unseen, acknowledged.

Our company is proud to be a founding member of the Rosalind Franklin Society’s Council on Corporate Leadership. This Council focuses on recognizing and fostering the contributions of women and minorities across scientific professions and institutions. The importance of fostering such work is fundamental to our core values, having named our company in honor of Rosalind Franklin and her pioneering spirit as we strive to empower all scientists in collaborative discoveries that transform our world.

The mission of the Council on Corporate Leadership is to create a more diverse landscape for scientific achievements, in a way that powerfully recognizes important work by every scientist.    

In the coming months, the Council on Corporate Leadership will be building its base of corporate partners and engaging them on strategies to recognize great achievements while addressing inequities of women and minorities in science. The Council will convene at a dedicated colloquium during the RFS annual board meeting this December, featuring Nobel Laureates, senior scientists as well as young researchers and leaders of promise. The Council will also be supporting the financing and allocation of the Rosalind Franklin Award given annually to pioneering women in the industrial, biotechnology, and agriculture sectors who have made significant contributions to the advancement of the bio-based economy and biotech innovation.

Rosalind is very excited to be part of this important new initiative and we encourage our colleagues to get involved. Those interested in becoming a corporate partner should reach out to Cassandra Wesselman by emailing: cassandra@rosalind.bio

Opening a new door to discovery, ROSALIND now empowers scientists to explore experiment results by key terms (Pathways, Signatures, Diseases and Drugs) that are significantly enriched across all samples using GSVA scores. You can access Term Exploration within the Discovery and Analysis section of each experiment. ROSALIND has been pre-computing these scores for the past several months, so many existing experiments already have this new analysis ready for exploration.

Every experiment and scientific question seeks to find insights on biological processes and pathways. Prior to now, this scientific journey always began with an exploration of genes to uncover the changes to underlying pathways. Now, you can begin exploring Pathways and significant Terms regardless of comparisons or cut-offs.

Our latest ROSALIND update v3.16 is now live and delivers enhancements for collaboration, 10X Single Cell RNA (scRNA-seq), Pathway Enrichment and more.

VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.

St. Louis, MO /PR Newswire/—Canopy Biosciences, a multi-omic CRO providing NanoString® nCounter® and RNA Seq services to both clinical and research customers, has partnered with Onramp BioInformatics™ to offer their ROSALIND™ interactive data analysis platform for Canopy’s gene expression services.  Launched earlier this year, Canopy has been providing this intuitive platform to customers that have run NanoString and RNA Seq projects.

NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, today announced a collaboration for the development of new analysis tools for data generated on NanoString’s nCounter® Analysis System. The new analysis functionality is built into ROSALIND™, OnRamp’s cloud-based analysis suite that facilitates data visualization, exploration and collaboration. The companies are releasing these new capabilities through early access and immediately offering it to COVID-19 researchers performing critical host response studies on the nCounter platform.

We’ve all been reminded across various social media feeds how Isaac Newton discovered calculus while “social distancing” during the Great Plague of London or how some of Shakespeare’s greatest works happened while in quarantine. Although the thought of being able to work from home was once a dream we wished for, as Adam Ruben, Ph.D. puts it, science-ing from home isn’t easy.

If juggling your altered home-life alongside the 9-5 work routine wasn’t challenging enough, it’s even more questionable how you can advance your research now that you have limited access to your laboratory, your data and your team.

As we all grapple with the new reality of lockdowns and work-from-home mandates, there’s now a new opportunity re-define what it truly means to do collaborative research and remote science anywhere in the world.

Updated: June 25, 2020 ------
The COVID-19 Research Community Showcase

The COVID-19 Research Community unites scientists across the globe in the shared purpose of accelerating our collective understanding of COVID-19 and the SARS-CoV-2 virus. Researchers working on COVID-19 receive complimentary Community Scientist access to ROSALIND and the NanoString Early Access Program to facilitate rapid data analysis with real-time, global collaboration.

Today, we enhanced the COVID-19 Research Community through the addition of a new Showcase. ROSALIND Showcases provide a new experience for collaboration by summarizing highlights, capturing key observations and empowering community scientists with a library of COVID-related datasets, including some of the most recent research. 

The COVID-19 Research Community Showcase is accessible publicly at this link: https://rosalind.onramp.bio/showcase/covid19

Join the community effort to share, discover and accelerate our collective understanding of COVID-19.

Updated: May 20, 2020 ------
NanoString Early Access Program and the COVID-19 Community

Today, we announced our collaboration with NanoString for the development of new analysis tools for data generated on NanoString’s nCounter® Analysis System. This new analysis functionality is now built into ROSALIND™ and facilitates data visualization, exploration and collaboration for COVID-19 researchers performing critical host response studies on the nCounter platform.

As of the Early Access Program launched today, ROSALIND natively supports the NanoString COVID Panel Plus with targeted gene expression on human immune response with 10 supplemental genes (8 SARS-CoV-2 plus ACE2 human and ACE2 mouse). This new solution incorporates the methods and algorithms of NanoString nSolver and their Advanced Analysis solution within ROSALIND to accelerate insights from the nCounter instrument and empower global collaboration. 

Through the Early Access Program scientists and researchers are empowered with an end-to-end solution that streamlines the extraction, quantification, data analysis and collaboration to provide deeper insights into the gene expression of human immunology together with the viral response experienced during COVID-19.   

Updated: April 12, 2020 ------
COVID-19 Community Enablement - SARS-CoV-2 Genome & Virology

The SARS-CoV-2 genome is now available for new experiments and to support the COVID-19 Community. This facilitates analysis and discovery into the viral gene expression of COVID-19. Many of the recent NCBI public data submissions with SARS-CoV-2 samples and COVID-19 patient samples have already been processed and added to the Community Space.

ROSALIND Pathways has added a new Virology category and collection of Knowledge Bases to enhance COVID-19 research. New entries include Pathogen-Host Interactome (P-HIPSTer) and GEO Virus Perturbations. 

New COVID-19 datasets now available in the Community Space:

• Transcriptional response of human lung epithelial cells to SARS-CoV-2 infection (PRJNA615032)
• LY6E blocks coronavirus fusion and confers immune control of viral disease (PRJNA609134)
• Washington SARS-CoV-2 isolate sequences (PRJNA610428)
• Severe acute respiratory syndrome coronavirus 2 Raw sequence reads (PRJNA605983)
• Metatranscriptomics of two COVID-19 pneumonia cases (PRJNA601736)
• Relative timing of type I interferon response and virus replication determines disease outcome during MERS-CoV infection (PRJNA545350)

Updated: March 30, 2020 ------
Support for the SARS-CoV-2 Genome is in development now and will be released next week. We will also be posting several new public datasets from multiple locations across the globe. It's imperative that we join forces globally in open data sharing on COVID-19 so that we may track the strains, measure the progression of the disease and assess the efficacy of treatments.

If you have COVID-19 datasets, upload them today for free processing and interpretation.

Originally Posted: Jan 25, 2020 ------

Seeing the news on the growing threat of a Coronavirus pandemic, I’m reminded of just how interconnected we all are on this planet. Within a few short weeks, this deadly virus managed to make its way across species and oceans to a dozen different countries, affecting thousands of people. We still don’t know how severe this strain of Coronavirus will be and it’s hard not to be driven to join the fight against it.

We live in an era of unprecedented genomic technology with brilliant scientists that work tirelessly each day to gain deeper understanding into the inner workings of our biology and the diseases that afflict us. I believe that our greatest work stands before us and will be achieved through collaboration. While technical, organizational or resource constraints often slow our progress in other areas, we can overcome these now to collaborate for the cure.

Today we've launched the Coronavirus Community Space to provide open-access of ROSALIND, our discovery and collaboration platform, for fellow scientists who wish to join a community effort to share, discover and accelerate our collective understanding of Coronavirus.